These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 23829549

  • 21. Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
    McBride CM, Renhowe PA, Heise C, Jansen JM, Lapointe G, Ma S, Piñeda R, Vora J, Wiesmann M, Shafer CM.
    Bioorg Med Chem Lett; 2006 Jul 01; 16(13):3595-9. PubMed ID: 16603352
    [Abstract] [Full Text] [Related]

  • 22. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
    Liu Y, Lang Y, Patel NK, Ng G, Laufer R, Li SW, Edwards L, Forrest B, Sampson PB, Feher M, Ban F, Awrey DE, Beletskaya I, Mao G, Hodgson R, Plotnikova O, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.
    J Med Chem; 2015 Apr 23; 58(8):3366-92. PubMed ID: 25763473
    [Abstract] [Full Text] [Related]

  • 23. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
    Certal V, Carry JC, Halley F, Virone-Oddos A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Karlsson A, Charrier V, Delorme C, Rak A, Abecassis PY, Amara C, Vincent L, Bonnevaux H, Nicolas JP, Mathieu M, Bertrand T, Marquette JP, Michot N, Benard T, Perrin MA, Lemaitre O, Guerif S, Perron S, Monget S, Gruss-Leleu F, Doerflinger G, Guizani H, Brollo M, Delbarre L, Bertin L, Richepin P, Loyau V, Garcia-Echeverria C, Lengauer C, Schio L.
    J Med Chem; 2014 Feb 13; 57(3):903-20. PubMed ID: 24387221
    [Abstract] [Full Text] [Related]

  • 24. Synthesis, kinase inhibitory potencies and in vitro antiproliferative activity of isoindigo and 7'-azaisoindigo derivatives substituted by Sonogashira cross-coupling.
    Bouchikhi F, Anizon F, Moreau P.
    Eur J Med Chem; 2009 Jun 13; 44(6):2705-10. PubMed ID: 19232788
    [Abstract] [Full Text] [Related]

  • 25. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M, Takami A, Okada Y, Kawata T, Tagami Y, Ohashi H, Sato M, Sugiyama T, Fukushima K, Iijima H.
    Bioorg Med Chem; 2007 Jan 01; 15(1):350-64. PubMed ID: 17046269
    [Abstract] [Full Text] [Related]

  • 26. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5633-7. PubMed ID: 21798738
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
    Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, Huffman WF, Koretke-Brown KK, Lai ZV, McDonald OB, Nakamura H, Newlander KA, Oleykowski CA, Parrish CA, Patrick DR, Plant R, Sarpong MA, Sasaki K, Schmidt SJ, Silva DJ, Sutton D, Tang J, Thompson CS, Tummino PJ, Wang JC, Xiang H, Yang J, Dhanak D.
    J Med Chem; 2010 May 27; 53(10):3973-4001. PubMed ID: 20420387
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
    Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D'Alessio R, Fiorentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, Vianello P, Vulpetti A, Ciomei M.
    J Med Chem; 2009 Aug 27; 52(16):5152-63. PubMed ID: 19603809
    [Abstract] [Full Text] [Related]

  • 36. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
    Zhu Y, Liu Z, Qu Y, Zeng J, Yang M, Li X, Wang Z, Su J, Wang X, Yu L, Wang Y.
    Cancer Chemother Pharmacol; 2020 Jul 27; 86(1):33-43. PubMed ID: 32519033
    [Abstract] [Full Text] [Related]

  • 37. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.
    Chem Biol Drug Des; 2012 Aug 27; 80(2):328-39. PubMed ID: 22583481
    [Abstract] [Full Text] [Related]

  • 38. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
    Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.
    Proc Natl Acad Sci U S A; 2018 Feb 20; 115(8):1913-1918. PubMed ID: 29434041
    [Abstract] [Full Text] [Related]

  • 39. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2969-74. PubMed ID: 21470862
    [Abstract] [Full Text] [Related]

  • 40. Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.
    Wang X, Berger DM, Salaski EJ, Torres N, Dutia M, Hanna C, Hu Y, Levin JI, Powell D, Wojciechowicz D, Collins K, Frommer E, Lucas J.
    J Med Chem; 2010 Nov 11; 53(21):7874-8. PubMed ID: 20961062
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.